Detalhe da pesquisa
1.
Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function.
Br J Clin Pharmacol
; 88(1): 237-247, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34169560
2.
Evaluation of drug-drug interactions of pemigatinib in healthy participants.
Eur J Clin Pharmacol
; 77(12): 1887-1897, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34282472
3.
Correction to: Evaluation of drugdrug interactions of pemigatinib in healthy participants.
Eur J Clin Pharmacol
; 77(12): 1899, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34436632
4.
Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110.
Drug Metab Dispos
; 43(4): 485-9, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605813
5.
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.
J Am Acad Dermatol
; 67(4): 658-64, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22281165
6.
Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
J Clin Pharmacol
; 61(7): 954-960, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434286
7.
Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans.
Drug Metab Dispos
; 38(11): 2023-31, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20699411
8.
An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
J Clin Pharmacol
; 60(11): 1519-1526, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32515832
9.
Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
Clin Pharmacol Drug Dev
; 9(6): 677-688, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821750
10.
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
J Clin Pharmacol
; 60(8): 1022-1029, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32149388
11.
Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
J Clin Pharmacol
; 59(12): 1641-1647, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31282592
12.
Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor.
J Clin Pharmacol
; 56(11): 1344-1354, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26990117
13.
Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study.
Clin Pharmacol Drug Dev
; 3(3): 207-14, 2014 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27128611
14.
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
J Clin Pharmacol
; 54(12): 1354-61, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24965573
15.
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients.
Clin Pharmacol Drug Dev
; 3(1): 34-42, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27128228
16.
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
J Clin Pharmacol
; 52(6): 809-18, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21602517
17.
The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers.
J Clin Pharmacol
; 51(12): 1644-54, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21257798
18.
Tramadol pharmacokinetics and its possible interactions with cyclooxygenase 2-selective nonsteroidal anti-inflammatory drugs.
Clin Pharmacol Ther
; 75(4): 363-5, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15060515